arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Allarity Therapeutics, Inc.

ALLR

$1.10 ▼ -0.06 (-5.17%) at close

7 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Allarity Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $15.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -128.3% ↗

FCF / Share $-1.03 ↗

Trailing P/E —

Price / Book 1.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 22, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-11.23M

↑ +54.2% —

FCF / Share Free cash flow per share

$-1.03

↑ +90.6% —

Long-Term Debt Long-term obligations

$2.69M

↑ +1.6% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	95.0% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	99.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-272810.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	47.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-106.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	54.2% Excellent ↑ Excellent Improving Year-over-year change in net income	-106.0% Weak ↓ Weak Declining Year-over-year change in net income	25.9% Excellent ↑ Excellent Improving Year-over-year change in net income	39.7% Excellent Excellent Year-over-year change in net income	-302.7% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	90.6% Excellent Excellent Year-over-year change in free cash flow	—	—	25.3% Excellent Excellent Year-over-year change in free cash flow	-6.5% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.7% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
FCF / Net Income (x)	1.32x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.56x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-128.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-227.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	26952.0% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-1075.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-115.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-26.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-69.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-120.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-144.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-237.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-24.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-114.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-862%)	-207.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1484%)	—	—	-146.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1079%)	-27.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-281%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	—	—	-0.98x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-263%)	-23.40x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-4000%)	—	—	—
Interest Coverage (x)	—	-64.40x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-503.79x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-2871.92x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-268.24x Weak Weak Operating income divided by interest expense Optimal: > 5x	-89.45x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-14.69M	$-19.53M	$2.52M	$2.64M	—	—	—
Debt / EBITDA (x)	—	—	-0.16x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.08x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.02	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-0.78	$-15.65	$-6.03K	$-2.21	$-4.19	$-2.03	—
Free Cash Flow per Share (USD)	$-1.03	$-10.98	—	$-1.77	$-2.37	$-2.22	—
Book Value per Share (USD)	$0.61	$1.62	—	$-0.01	$2.24	$5.75	—
Tangible Book Value per Share (USD)	$0.61	$1.62	—	$-0.61	$-1.23	$-1.42	—
Basic Weighted Avg Shares (shares)	14.38M	1.61M	3,385	9.53M	6.36M	3.26M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$9.50M	$11.50M	$-12.20M	$-6.25M	$335.00K	$-3.82M	—
LT Debt (USD)	—	—	$2.69M	$2.64M	—	—	—
Total Equity (USD)	$9.83M	$11.81M	$-2.75M	$-113.00K	$18.15M	$24.44M	$20.04M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$320.00K	—	—	—	—	—	—
Depreciation Expense (USD)	—	$9.00K	$37.00K	$60.00K	$106.00K	$46.00K	—
Net Income, GAAP (USD)	$-11.23M	$-24.52M	$-11.90M	$-16.06M	$-26.65M	$-6.62M	—
Operating Cash Flow (USD)	$-14.82M	$-17.35M	$-12.74M	$-16.82M	$-15.05M	$-7.25M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters

Allarity Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ALLR with peers